Obligation under form 2-A of DPCO, 1987

2068. SHRI RAJNI RANJAN SAHU: Will the PRIME MINISTER be pleased *to* refer to the answer to Unstarred Question 660 given in the Rajya Sabha on the 5th September, 1991 and state;

(a) whether it is a fact that under form 2-A of DPCO, 1987 it is obligatory on the part of producers *to* disclose details in respect of price decontrolled medicines;

(b) if so, what is the break up of ex-factory cost and MAPE on Ceftazidine Hcl Injections sold under the brand name Fortum and when these details were communicated;

(c) what was the price of these formulations prior to their recent price revision consequent *to* withdrawal of custom duty on the bulk drug ceftazidine;

(d) whether any programme for the manufacture of this drug in the country has been approved; and

(e> if so, the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) Yes, Sir.

(b) Information as communicated by the company in Form 2A on 26-U-91 is given in the statement- (See below) Company is now going to manufacture the formulation in the country. So far, it was importing the formulation in finished form.

(c) With effect from 25-7-91, bulk drag Ceftazidine is exempt from customs duty. The price of various packs as reported by the company in form 3 in March, 1991, were as under:

Fortum Inj. 250 mg. V. —
Rs. *66.21* 500" —Rs.
131.*93* 1.0" —Rs.
26283

(d) and (e) Yes, Sir, M/s. Glaxo has been given licence to manufacture Ceftazi dine dm for a capacity of 59 kg a year.

Statement

Fortum Injection

Break-up	1.09 gm	0.59 gm	0.25 gm
	(in Rs.)		
(a) Material Cost	98.82	49.41	24.70
(b) Conversion Cost	0.42	0.42	0.42
(c) Packing Material Cost	11.01	10.92	10.68
(d) Packing Charges	0.08	0.08	0.08
(e) Ex-Factory Cost (a) to (d)	110.33	60.83	35.88
(f) MAPE (128%)	141.22	77.86	45.93
(g) Excise duty	29.40	16.21	9.56
(h) Retail Price b	280.95	154.90	91.3

Observation of Public Accounts Committee on custom duty concessions

2069. SHRI BEKAL UTSAHI: WiU the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 656 given in the Rajya Sabha on the 5th September, 1991 and state;

(a) whether it is a fact that Public Accounts Committee had observed that custom duty concessions are being given to

benefit the producer and the benefit of these concessions is not being passed on the public;

(b) if so, the details thereof;

(c) whether Government are evolving any institutional arrangement to monitor prices and production of bulk drugs linked to duty Concessions in Consultation with Ministry of Finance;

(d) if so, the details thereof;

(e) whether Government 'have made any reference to Finance Ministry in tfois regard; and

(f) if so, by when and if not, the reasons therefor?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) The information is being collected and will be laid On the Table of the House.

(c) to (f) The question of constituting a cell to monitor the effect of duty concession is still under examination.

Revising the liability assessed by the Special Team

2070. SHRI BEKAL UTSAHL Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 670 given in the Rajya Sabha on the 5th September, 1991 and state:

(a) whether it is a fact that liability of Rs. 12 crores as assessed by the Special Team has already been revised to Rs. ill crores.

(b) whether it is also a fact that on the one hand charges against the members of Special Team and Former Development Commissioner have not been framed and on the other hand cases against them have been closed by officers who were not competent to do so;

(c) if so, names of the officers and their designations; and

(d) whythe. investiagtion was not entrusted to Central Vigilance Commissioner or CAG and why it was done by officers who in one or other way were a party to the entire melodrama?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) The liability of 12 companies involved in Supreme Court cases as assessed at Rs. 13.56 crores by Special Team has been revised to Rs. 111.32 crores.

(b) to (d) There have been some complaints against the members of Special Team and Former Development Commissioner which are being examined in the department and a final view is yet to be taken.

Price of each formulation pack of Beta-methasone of M/s. daxo

2071. SHRI BEKAL UTSAHI: WiU the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1621 given in the Rajya Sabha on the 12th September, 1991 and state:

(a) what was the price of each formu lation pack of Betamethasone of M/s. Glaxo which was stayed by Delhi high Court in 1981;

(b) what are the prices of each pack of formulations which could not be an nounced because of the stay;

(c) when the price was revised under DPCO 1987, what was the price of each pack and when the revised price was implemented; and

(d) what steps have been taken to to the responsibility of those who supressed the liability of Rs. 37 crores only?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (c) The information wfll he compiled and laid on the Table of the House as soon as possible.

(d) Since the case is subjudice, an ap-propriate view could be taken only after the Mability is finally determined.